Wedbush Research Analysts Boost Earnings Estimates for VERA

Vera Therapeutics, Inc. (NASDAQ:VERA - Free Report) - Investment analysts at Wedbush boosted their Q2 2025 earnings estimates for shares of Vera Therapeutics in a research report issued to clients and investors on Monday, June 9th. Wedbush analyst L. Chico now forecasts that the company will post earnings of ($0.70) per share for the quarter, up from their previous forecast of ($0.71). Wedbush has a "Neutral" rating and a $26.00 price objective on the stock. The consensus estimate for Vera Therapeutics' current full-year earnings is ($2.89) per share. Wedbush also issued estimates for Vera Therapeutics' Q3 2025 earnings at ($0.79) EPS, Q4 2025 earnings at ($0.89) EPS, FY2025 earnings at ($3.19) EPS, Q1 2026 earnings at ($0.94) EPS, Q2 2026 earnings at ($1.01) EPS, Q3 2026 earnings at ($1.08) EPS, Q4 2026 earnings at ($0.93) EPS, FY2026 earnings at ($3.95) EPS, FY2027 earnings at ($3.34) EPS, FY2028 earnings at ($1.94) EPS and FY2029 earnings at ($1.01) EPS.

VERA has been the topic of a number of other research reports. HC Wainwright reaffirmed a "buy" rating and issued a $85.00 price target (up previously from $75.00) on shares of Vera Therapeutics in a research note on Monday, June 2nd. Cantor Fitzgerald lowered their target price on shares of Vera Therapeutics from $107.00 to $100.00 and set an "overweight" rating on the stock in a report on Wednesday, May 7th. JPMorgan Chase & Co. decreased their price objective on shares of Vera Therapeutics from $77.00 to $71.00 and set an "overweight" rating on the stock in a report on Tuesday, March 4th. Scotiabank reiterated an "outperform" rating on shares of Vera Therapeutics in a report on Tuesday, June 3rd. Finally, Guggenheim restated a "buy" rating on shares of Vera Therapeutics in a research note on Tuesday, June 3rd. One investment analyst has rated the stock with a hold rating, seven have issued a buy rating and two have issued a strong buy rating to the company's stock. Based on data from MarketBeat.com, the company currently has a consensus rating of "Buy" and an average target price of $65.00.

Vera Therapeutics Stock Up 1.0%

VERA traded up $0.22 during trading on Wednesday, reaching $22.74. The company had a trading volume of 1,306,850 shares, compared to its average volume of 947,892. The company has a debt-to-equity ratio of 0.17, a current ratio of 13.76 and a quick ratio of 13.76. Vera Therapeutics has a 12 month low of $18.53 and a 12 month high of $51.61. The business's fifty day moving average price is $22.52 and its 200 day moving average price is $30.75. The company has a market cap of $1.45 billion, a P/E ratio of -8.71 and a beta of 1.13.

Vera Therapeutics (NASDAQ:VERA - Get Free Report) last released its quarterly earnings results on Thursday, May 8th. The company reported ($0.81) EPS for the quarter, missing analysts' consensus estimates of ($0.75) by ($0.06). During the same period in the prior year, the business earned ($0.56) earnings per share.

Institutional Investors Weigh In On Vera Therapeutics

Several institutional investors and hedge funds have recently bought and sold shares of the company. Rhumbline Advisers lifted its holdings in shares of Vera Therapeutics by 7.9% in the first quarter. Rhumbline Advisers now owns 63,189 shares of the company's stock worth $1,518,000 after acquiring an additional 4,600 shares during the last quarter. Jane Street Group LLC lifted its holdings in shares of Vera Therapeutics by 297.1% in the first quarter. Jane Street Group LLC now owns 41,578 shares of the company's stock worth $999,000 after acquiring an additional 62,678 shares during the last quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC lifted its holdings in shares of Vera Therapeutics by 22.4% in the first quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC now owns 98,013 shares of the company's stock worth $2,354,000 after acquiring an additional 17,907 shares during the last quarter. Dynamic Technology Lab Private Ltd bought a new position in shares of Vera Therapeutics in the first quarter worth about $326,000. Finally, Parkman Healthcare Partners LLC bought a new position in shares of Vera Therapeutics in the first quarter worth about $1,829,000. Institutional investors own 99.21% of the company's stock.

About Vera Therapeutics

Vera Therapeutics, Inc, a clinical stage biotechnology company, focuses on developing and commercializing treatments for patients with serious immunological diseases. Its lead product candidate is atacicept, a fusion protein self-administered as a subcutaneous injection that is in Phase III clinical trial for patients with immunoglobulin A nephropathy; and for treatment of lupus nephritis that is in Phase II clinical trial.